PARP inhibitors in ovarian cancer. (February 2019)

• Record Type: Journal Article
• Authors: Franzese, Elisena; Centonze, Sara; Diana, Anna; Carlino, Francesca; Guerrera, Luigi Pio; Di Napoli, Marilena; De Vita, Ferdinando; Pignata, Sandro; Ciardiello, Fortunato; Orditura, Michele
• Is Part Of: Cancer treatment reviews. Volume 73(2019)
• Page Start: 1
• Page End: 9
• Publication Date: 2019-02
• Subjects: Ovarian cancer -- PARP inhibitors -- Olaparib -- Niraparib -- Rucaparib; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2018.12.002
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: Ovarian cancer is the most lethal gynecologic malignancy. PARP inhibitors are effective therapeutic agents by inducing synthetic lethality. FDA and EMA approved PARP inhibitors in ovarian cancer: olaparib, rucaparib, and niraparib. Combinations of PARP inhibitors with other agents may overcome resistance mechanisms. Abstract: Poly-ADP-ribose polymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways, particularly homologous recombination (HR) deficiency. In this review, we provide an updated overview of the available results of recent clinical trials on the three Food and Drug Administration and European Medicines Agency approved PARPis in ovarian cancer: olaparib, niraparib, and rucaparib. Furthermore, we anticipate the future perspective of combination regimens with antiangiogenic, immunocheckpoint inhibitors, and other biological agents as strategies to overcome resistance mechanisms, potentiate the therapeutic efficacy, and expand their clinical use in non-HR deficient tumors.